Nicole D Perry Apellis Pharmaceuticals, Inc. (APLS) insider trading activity

Nicole D Perry is Vice President - Accounting of Apellis Pharmaceuticals, Inc.. Currently has a direct ownership of 4,847 shares of APLS, which is worth approximately $133,050. The most recent transaction as insider was on Aug 02, 2021, when has been sold 1,000 shares (Common Stock) at a price of $63.99 per share, resulting in proceeds of $63,990. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 4.85K

0% 3M change

0% 12M change

Total Value Held $133,050

Nicole D Perry Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Aug 02 2021	SELL Open market or private sale	$63,990 $63.99 p/Share	1,000 Reduced 17.1%	4,847 Common Stock
Aug 02 2021	BUY Exercise of conversion of derivative security	$3,760 $3.76 p/Share	1,000 Added 14.6%	5,847 Common Stock
Jul 01 2021	SELL Open market or private sale	$64,000 $64.0 p/Share	1,000 Reduced 17.1%	4,847 Common Stock
Jul 01 2021	BUY Exercise of conversion of derivative security	$3,760 $3.76 p/Share	1,000 Added 14.6%	5,847 Common Stock
Jun 11 2021	SELL Open market or private sale	$61,550 $61.55 p/Share	1,000 Reduced 17.1%	4,847 Common Stock
Jun 11 2021	BUY Exercise of conversion of derivative security	$3,200 $3.2 p/Share	1,000 Added 14.6%	5,847 Common Stock
Jun 01 2021	SELL Open market or private sale	$56,400 $56.4 p/Share	1,000 Reduced 17.1%	4,847 Common Stock
Jun 01 2021	BUY Exercise of conversion of derivative security	$3,760 $3.76 p/Share	1,000 Added 14.6%	5,847 Common Stock
May 03 2021	SELL Open market or private sale	$50,730 $50.73 p/Share	1,000 Reduced 17.1%	4,847 Common Stock
May 03 2021	BUY Exercise of conversion of derivative security	$3,760 $3.76 p/Share	1,000 Added 14.6%	5,847 Common Stock
Apr 30 2021	SELL Open market or private sale	$50,000 $50.0 p/Share	1,000 Reduced 17.1%	4,847 Common Stock
Apr 30 2021	BUY Exercise of conversion of derivative security	$3,760 $3.76 p/Share	1,000 Added 14.6%	5,847 Common Stock
Mar 01 2021	SELL Open market or private sale	$100,000 $50.0 p/Share	2,000 Reduced 46.01%	2,347 Common Stock
Mar 01 2021	BUY Exercise of conversion of derivative security	$7,520 $3.76 p/Share	2,000 Added 31.51%	4,347 Common Stock
Feb 10 2021	SELL Payment of exercise price or tax liability	$7,301 $47.72 p/Share	153 Reduced 6.12%	2,347 Common Stock
Feb 09 2021	SELL Open market or private sale	$100,000 $50.0 p/Share	2,000 Reduced 44.44%	2,500 Common Stock
Feb 09 2021	BUY Exercise of conversion of derivative security	$7,520 $3.76 p/Share	2,000 Added 30.77%	4,500 Common Stock
Jan 28 2021	BUY Grant, award, or other acquisition	-	2,500 Added 50.0%	2,500 Common Stock
Jan 04 2021	SELL Open market or private sale	$114,480 $57.24 p/Share	2,000 Reduced 100.0%	0 Common Stock
Jan 04 2021	BUY Exercise of conversion of derivative security	$7,520 $3.76 p/Share	2,000 Added 50.0%	2,000 Common Stock
Dec 04 2020	SELL Open market or private sale	$900,000 $50.0 p/Share	18,000 Reduced 100.0%	0 Common Stock
Dec 04 2020	BUY Exercise of conversion of derivative security	$67,680 $3.76 p/Share	18,000 Added 50.0%	18,000 Common Stock

NDP

Nicole D Perry

Vice President - Accounting

Waltham, MA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells APLS shares.

Notify only if

Value

Insider Trading

Get notified when an Apellis Pharmaceuticals, Inc. insider buys or sells APLS shares.

Notify only if

Operation

Value

Type

News

Receive news related to Apellis Pharmaceuticals, Inc.

Track Activities on APLS

Account